维普中文期刊产品整合服务

Clinical Practice Guidelines and Experts’Consensuses for Treatment of Coronavirus Disease 2019(COVID-19)Patients with Chinese Herbal Medicine:A Systematic Review

查看全文 作　　者：LI Yu-[1]xi;LI [1,2]Juan;ZHANG [2]Yue;TIAN Yan-[2]ping;ZHANG Yong-[3]gang;JIN Rong-[2]jiang;GUO [4]Yan;Mike [5]Clarke 高影响力作者 机构地区：[1]School of Acupuncture-Moxibustion and Tuina,Chengdu University of Traditional Chinese Medicine,Chengdu(610032),China;[2]School of Health Preservation and Rehabilitation,Chengdu University of Traditionai Chinese Medicine,Chengdu(610032),China;[3]West China Hospital,Sichuan University,Chengdu(610032),China;[4]Xiyuan Hospital,China Academy of Chinese Medicine Sciences,Beijing(100091),China;[5]Northern Ireland Clinical Trials Unit and Methodology Hub,Centre for Public Health,Queen's University Belfast,Belfast,UK高影响力机构 出　　处：《Chinese Journal of Integrative Medicine》索引2020年第26卷第10期,共8页高影响力期刊 基　　金：Supported by Education Fund of Chengdu University of Traditional Chinese Medicine。 摘　　要：Objective:To systematically review the clinical practice guidelines for the treatment of coronavirus disease 2019(COVID-19)patients with Chinese herbal medicine(CHM),summarize their recommendations and evaluate their qualities.Methods:Electronic databases,websites of governments,academic associations or organizations for eligible guidelines were searched up to April 2020.Information were extracted to summarize recommendations for the use of Chinese herbal formulae and Chinese patent medicine(CPM)for COVID-19 patients.The methodological quality and reporting quality of the included guidelines were independently evaluated,using the Appraisal of Guidelines for REsearch and Evaluation(AGREE)Ⅱtool and Reporting Items for Practice Guidelines in healthcare(RIGHT)statement,respectively.Results:Totally 45 guidelines were identififi ed:42(93%)suggested specific CM formulae for treating COVID-19 patients;and 35(78%)assigned patients diagnosed with COVID-19 to 4 stages(early,development,critical and recovery).The recommended formulae and CPMs for each stage with diverse syndrome types have been summarized.Most of the included guidelines were of low methodological quality,with only one achieving moderate quality of AGREEⅡ.The frequency with which the 35 items in the Reporting Items for Practice Guidelines in Healthcare(RIGHT)checklist were reported averaged 36.5%across the 45 guidelines.Conclusions:This systematic review has summarized current recommendations for treating COVID-19 patients with CHM and shows that the general quality of present guidelines is quite low.The development of future guidelines should include increased awareness of the features of good quality guidelines. 关 键 词：coronavirus disease 2019 COVID-19 Chinese medicine herbal medicine clinical practice guideline systematic review
相关文献

参考文献(72)

引证文献(3)

耦合文献(2909)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费